HUTCHMED (China) Ltd (NAS:HCM)
$ 17.37 0.01 (0.06%) Market Cap: 3.04 Bil Enterprise Value: 2.33 Bil PE Ratio: 0 PB Ratio: 4.12 GF Score: 68/100

Hutchison China MediTech Ltd Investor Update at ASCO Transcript

Jun 01, 2020 / 12:00PM GMT
Release Date Price: $21.99 (+0.83%)
Christian Lawrence Hogg;China;Limited;Former CEO;Executive Director
HUTCHMED

()-&

Okay. So I think we're live now. So welcome, everybody, to the Hutchison China MediTech conference call today to talk about ASCO and some of the other things that are going on in our business.

My name is Christian Hogg. I'm the CEO of Chi-Med. I have also on the line Dr. Wei-Guo Su, our Chief Scientific Officer; and Dr. Marek Kania, our Chief Medical Officer, for our international operations based out of New Jersey.

Today, if you go to Page #3 on the presentation, we'll be covering a few subjects. First of all, savolitinib Exon 14 skipping non-small cell lung cancer, the presentation of the registration study data that was presented or that was published today in full on the virtual ASCO site.

Second, Wei-Guo will also take you through the data from the SAVOIR study, the papillary renal cell carcinoma study of savolitinib. And then Marek will take you through the international data, the U.S. data on surufatinib and also give an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investorsā€™ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot